Grant Number:	1R01CA160744-01A1 Interpret this number
Primary Investigator:	Kim, Jane
Organization:	Harvard University D/B/A Harvard School Of Public Health
Project Title:	Comparative and Cost-Effectiveness of Preventing HPV-Related Diseases
Fiscal Year:	2012

DESCRIPTION (provided by applicant): Each year, more than 25,000 cases of invasive cancer attributable to human papillomavirus (HPV) infection occur in the United States; nearly 50% are cervical cancer, while the rest involve the oral cavity/oropharynx, anus, vulva, penis, and vagina. Collectively, these account for substantial morbidity and mortality, contribute to health disparities, and are associated with high economic costs. Advancements in HPV-related cancer epidemiology, coupled with new (e.g., HPV-16,-18 vaccines, HPV DNA testing) and emerging (e.g., biomarkers, therapeutic vaccines) technologies provide a remarkable opportunity to improve cancer prevention efforts. However, critical challenges remain with respect to clinical decision-making and prevention policy, pertaining to knowledge gaps and heterogeneities in the natural history of different cancers, uncertainties in HPV type distribution following HPV-16,-18 vaccination, and the real-world clinical effectiveness of emerging technologies. We propose to employ a decision-analytic approach, developing a flexible modeling framework that will allow us to synthesize the best available data; evaluate the health and economic consequences of alternative strategies; explore the uncertainty around their outcomes; explicitly quantify the tradeoffs associated with different approaches; and inform timely clinical and policy questions. By achieving our aims, we expect to have an impact on (1) the analytic methods of decision science; (2) the equitable distribution and rationale use of new technology; (3) the effectiveness of strategies for cancer prevention through clinical guidelines and national policies; (4) HPV-related cancer outcomes, including reduced incidence, enhanced quality of life, improved survival, and reduced disparities; and (5) the financial and economic profile of delivering cancer-related health services. PUBLIC HEALTH RELEVANCE: Rapid advances in the fields of HPV-related cancer epidemiology and medical technology present opportunities to revolutionize the approach to cancer prevention in the U.S. but have outpaced the ability of policy makers to make informed decisions regarding optimal adoption of health interventions. In this project, we propose to develop a flexible modeling framework that will enable us to synthesize the best available data on HPV, provide insight into the comparative and cost-effectiveness of different strategies, and assist in informed public health and clinical decision-making with respect to prevention of HPV-related cancers.




Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men.
Authors: Burger E.A. , Dyer M.A. , Sy S. , Palefsky J.M. , De Pokomandy A. , Coutlee F. , Silverberg M.J. , Kim J.J. .
Source: Journal Of Acquired Immune Deficiency Syndromes (1999), 2018-05-09 00:00:00.0; , .
EPub date: 2018-05-09 00:00:00.0.
PMID: 29757775
Related Citations

Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Authors: Pedersen K. , Burger E.A. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: European Journal Of Cancer (oxford, England : 1990), 2018-01-12 00:00:00.0; 91, p. 68-75.
EPub date: 2018-01-12 00:00:00.0.
PMID: 29335156
Related Citations

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
Authors: Burger E.A. , Pedersen K. , Sy S. , Kristiansen I.S. , Kim J.J. .
Source: British Journal Of Cancer, 2017-09-05 00:00:00.0; 117(6), p. 783-790.
EPub date: 2017-08-03 00:00:00.0.
PMID: 28772279
Related Citations

Age of acquiring causal human papillomavirus (HPV) infections: Leveraging simulation models to explore the natural history of HPV-induced cervical cancer.
Authors: Burger E.A. , Kim J.J. , Sy S. , Castle P.E. .
Source: Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America, 2017-05-20 00:00:00.0; , .
EPub date: 2017-05-20 00:00:00.0.
PMID: 28531261
Related Citations

Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Authors: Kim J.J. , Burger E.A. , Sy S. , Campos N.G. .
Source: Journal Of The National Cancer Institute, 2017 02; 109(2), .
EPub date: 2016-10-18 00:00:00.0.
PMID: 27754955
Related Citations

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
Authors: Brisson M. , Bénard É. , Drolet M. , Bogaards J.A. , Baussano I. , Vänskä S. , Jit M. , Boily M.C. , Smith M.A. , Berkhof J. , et al. .
Source: The Lancet. Public Health, 2016 11; 1(1), p. e8-e17.
EPub date: 2016-09-27 00:00:00.0.
PMID: 29253379
Related Citations

The Cost-effectiveness Of Cervical Self-sampling To Improve Routine Cervical Cancer Screening: The Importance Of Respondent Screening History And Compliance
Authors: Burger E.A. , Sy S. , Nygård M. , Kim J.J. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2016-09-13 00:00:00.0; , .
PMID: 27624639
Related Citations

Cost-effective Management Of Women With Minor Cervical Lesions: Revisiting The Application Of Hpv Dna Testing
Authors: Pedersen K. , Burger E.A. , Sy S. , Kristiansen I.S. , Kim J.J. .
Source: Gynecologic Oncology, 2016-08-16 00:00:00.0; , .
PMID: 27542966
Related Citations

Racial And Ethnic Disparities In Human Papillomavirus-associated Cancer Burden With First-generation And Second-generation Human Papillomavirus Vaccines
Authors: Burger E.A. , Lee K. , Saraiya M. , Thompson T.D. , Chesson H.W. , Markowitz L.E. , Kim J.J. .
Source: Cancer, 2016-04-28 00:00:00.0; , .
PMID: 27124396
Related Citations

Cervical Cancer Screening In Low-resource Settings: A Cost-effectiveness Framework For Valuing Tradeoffs Between Test Performance And Program Coverage
Authors: Campos N.G. , Castle P.E. , Wright T.C. , Kim J.J. .
Source: International Journal Of Cancer, 2015-11-01 00:00:00.0; 137(9), p. 2208-19.
PMID: 25943074
Related Citations

Too Late To Vaccinate? The Incremental Benefits And Cost-effectiveness Of A Delayed Catch-up Program Using The 4-valent Human Papillomavirus Vaccine In Norway
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: The Journal Of Infectious Diseases, 2015-01-15 00:00:00.0; 211(2), p. 206-15.
PMID: 25057044
Related Citations

The value of improving failures within a cervical cancer screening program: an example from Norway.
Authors: Burger E.A. , Kim J.J. .
Source: International Journal Of Cancer, 2014-10-15 00:00:00.0; 135(8), p. 1931-9.
EPub date: 2014-10-15 00:00:00.0.
PMID: 24615416
Related Citations

Practice-based evidence for primary HPV testing in the United States.
Authors: Kim J.J. .
Source: Journal Of The National Cancer Institute, 2014 Aug; 106(8), .
PMID: 25038468
Related Citations

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Authors: Burger E.A. , Sy S. , Nygård M. , Kristiansen I.S. , Kim J.J. .
Source: Plos One, 2014; 9(3), p. e89974.
PMID: 24651645
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-31 00:00:00.0; 31 Suppl 7, p. H1-31.
PMID: 24332295
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-30 00:00:00.0; 31 Suppl 6, p. G1-31.
PMID: 24331817
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-12-29 00:00:00.0; 31 Suppl 5, p. F1-31.
PMID: 24331745
Related Citations

Comprehensive control of human papillomavirus infections and related diseases.
Authors: Bosch F.X. , Broker T.R. , Forman D. , Moscicki A.B. , Gillison M.L. , Doorbar J. , Stern P.L. , Stanley M. , Arbyn M. , Poljak M. , et al. .
Source: Vaccine, 2013-11-22 00:00:00.0; 31 Suppl 8, p. I1-31.
PMID: 24229716
Related Citations

Cost-effectiveness Of Surveillance Strategies After Treatment For High-grade Anal Dysplasia In High-risk Patients
Authors: Assoumou S.A. , Mayer K.H. , Panther L. , Linas B.P. , Kim J. .
Source: Sexually Transmitted Diseases, 2013 Apr; 40(4), p. 298-303.
PMID: 23486494
Related Citations

Modeling preventative strategies against human papillomavirus-related disease in developed countries.
Authors: Canfell K. , Chesson H. , Kulasingam S.L. , Berkhof J. , Diaz M. , Kim J.J. .
Source: Vaccine, 2012-11-20 00:00:00.0; 30 Suppl 5, p. F157-67.
PMID: 23199959
Related Citations